University of PittsburghUniversity of Pittsburgh
Startups
TechnologiesStartupsExpress LicensesCollectionsChat with AI
Sign in
University of Pittsburgh

Echogenesis Therapeutics

OverviewRequest InfoMore Like ThisExpress Licenses

Sector

Therapeutics

Therapeutic Areas

Otolaryngology

Therapeutic Indications

Hearing Loss

Founders

Chris CunninghamThanos TzounopoulosJosé P. Zevallos
Echogenesis Therapeutics

Echogenesis Therapeutics is developing gene therapies tailored to the cells and genetic changes involved in hearing loss. Its lead preclinical program targets congenital hearing loss associated with mutations in TOMT, using local delivery of a viral vector to supply a working gene to cochlear hair cells. The approach aims to restore hearing while limiting gene expression in other cell types. [1]

Founded by University of Pittsburgh researchers Chris Cunningham, Thanos Tzounopoulos and José P. Zevallos, Echogenesis builds on Pitt's expertise in hearing science and precision gene delivery. The team is advancing its research toward clinical translation, with support that includes an NIH small-business technology-transfer award. [2] [3]

Discover More with AI